Table 1.
Clinical characteristic of AS patients.
| M0 | M6 | |
|---|---|---|
| Age (years) | 31.23 ± 7.48 | |
| Males (n, %) | 27 (90) | |
| Duration (years)§ | 10 (5) | |
| NSAIDs (n, %) | 20 (66.7) | |
| SASP (n, %) | 5 (16.7) | |
| CRP (mg/L)§ | 11.25 (21.70) | 0.95 (4.25)*** |
| ESR (mm/h)§ | 14.00 (25.50) | 4.50 (6.25)*** |
| BASDAI§ | 5.23 (1.51) | 2.23 (2.72)*** |
| BASFI§ | 3.72 (2.64) | 1.60 (2.35)*** |
| BASMI§ | 2.50 (3.00) | 1.00 (3.00)** |
| ASDAS§ | 3.43 (1.29) | 1.33 (1.16)*** |
| Inactive† | 0 | 14 |
| Low activity† | 2 | 10 |
| High activity† | 15 | 5 |
| Very high activity† | 13 | 1 |
| BASDAI > 4† | 30 | 4 |
§Data expressed as median (IQR); †data expressed as frequency. Comparisons of CRP, ESR, BASDAI, BASFI, BASMI, and ASDAS between M0 and M6 were calculated using Wilcoxon rank-sum tests. **P ＜ 0.01, ***P ＜ 0.001. AS, ankylosing spondylitis; IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs; SASP, sulfasalazine; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; ASDAS, ankylosing spondylitis disease activity score; M0, baseline; M6, after 6 months of treatment.